Código QR (código de barras bidimensional)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Abstract Purpose To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. Methods This retrospective study obtained data from 202...

תיאור מלא

שמור ב:
Principais autores: Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng, Chao-Yuan Huang
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2023-06-01
סדרה:BMC Cancer
נושאים:
Prostatic neoplasms
Abiraterone acetate
Enzalutamide
Androgens
Castration
גישה מקוונת:https://doi.org/10.1186/s12885-023-10885-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים